P/E ratio for OpGen (OPGN)
P/E ratio as of April 2024 (TTM): -0.0415
According to OpGen 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.0414938. At the end of 2022 the company had a P/E ratio of -0.1842.
P/E ratio history for OpGen from 2015 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -0.1842 | -77.9% |
| 2021 | -0.8333 | -28.1% |
| 2020 | -1.16 | 1516.57% |
| 2019 | -0.0717 | -87.18% |
| 2018 | -0.5595 | 38.23% |
| 2017 | -0.4048 | -58.82% |
| 2016 | -0.9829 | -21.24% |
| 2015 | -1.25 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Lexicon Pharmaceuticals
LXRX | -2.32 | 5,499.70% | 🇺🇸 USA |
 Enzo Biochem ENZ | -1.12 | 2,604.84% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.